C.R. Bard, Inc. (NYSE:BCR) has received an average rating of “Hold” from the twelve research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $290.20.

Several equities analysts have recently issued reports on the company. Jefferies Group LLC reaffirmed a “hold” rating on shares of C.R. Bard in a research report on Thursday, August 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of C.R. Bard in a research report on Thursday, October 26th. BidaskClub lowered C.R. Bard from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. BMO Capital Markets reaffirmed a “hold” rating and issued a $317.00 price target on shares of C.R. Bard in a research report on Tuesday, July 11th. Finally, Zacks Investment Research lowered C.R. Bard from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/11/02/c-r-bard-inc-bcr-given-consensus-recommendation-of-hold-by-analysts.html.

C.R. Bard (NYSE:BCR) last posted its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.06. The firm had revenue of $989.80 million during the quarter, compared to analyst estimates of $990.64 million. C.R. Bard had a return on equity of 48.28% and a net margin of 14.75%. C.R. Bard’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.64 EPS.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be issued a dividend of $0.26 per share. The ex-dividend date of this dividend is Thursday, December 7th. This represents a $1.04 annualized dividend and a dividend yield of 0.32%. C.R. Bard’s dividend payout ratio (DPR) is 13.70%.

In other news, VP Betty D. Larson sold 5,906 shares of the company’s stock in a transaction that occurred on Friday, October 20th. The stock was sold at an average price of $330.16, for a total transaction of $1,949,924.96. Following the sale, the vice president now directly owns 10,753 shares of the company’s stock, valued at approximately $3,550,210.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David M. Barrett sold 3,344 shares of the company’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $327.31, for a total value of $1,094,524.64. The disclosure for this sale can be found here. Insiders have sold a total of 136,568 shares of company stock worth $43,932,079 over the last ninety days. Insiders own 0.80% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Alps Advisors Inc. raised its holdings in shares of C.R. Bard by 0.3% during the 2nd quarter. Alps Advisors Inc. now owns 1,921 shares of the medical instruments supplier’s stock worth $607,000 after acquiring an additional 5 shares in the last quarter. KCM Investment Advisors LLC raised its holdings in shares of C.R. Bard by 0.5% during the 2nd quarter. KCM Investment Advisors LLC now owns 2,187 shares of the medical instruments supplier’s stock worth $691,000 after acquiring an additional 10 shares in the last quarter. Parallel Advisors LLC raised its holdings in shares of C.R. Bard by 2.8% during the 2nd quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock worth $164,000 after acquiring an additional 14 shares in the last quarter. First Merchants Corp raised its holdings in shares of C.R. Bard by 0.6% during the 2nd quarter. First Merchants Corp now owns 5,135 shares of the medical instruments supplier’s stock worth $1,623,000 after acquiring an additional 32 shares in the last quarter. Finally, Advisor Partners LLC raised its holdings in shares of C.R. Bard by 4.9% during the 2nd quarter. Advisor Partners LLC now owns 1,360 shares of the medical instruments supplier’s stock worth $430,000 after acquiring an additional 63 shares in the last quarter. 79.27% of the stock is currently owned by institutional investors and hedge funds.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Analyst Recommendations for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.